The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions.

Autor: Khezri MR; Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran., Jafari R; Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute, Urmia University of Medical Sciences, Urmia, Iran., Yousefi K; Department of Molecular and Cellular Pharmacology, University of Miami-Miller School of Medicine, Miami, FL, USA., Zolbanin NM; Experimental and Applied Pharmaceutical Sciences Research Center, Urmia University of Medical Sciences, Urmia, Iran; Department of Pharmacology and Toxicology, School of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran. Electronic address: majidiz.n@umsu.ac.ir.
Jazyk: angličtina
Zdroj: Experimental and molecular pathology [Exp Mol Pathol] 2022 Aug; Vol. 127, pp. 104787. Date of Electronic Publication: 2022 May 27.
DOI: 10.1016/j.yexmp.2022.104787
Abstrakt: The human body consists of countless cells with the possibility of excessive and uncontrolled proliferation under certain dysregulated circumstances that could cause abnormal states such as cancer. Phosphatidylinositol 3 kinase (PI3K) and its downstream target, Protein kinase B or AKT, play a critical role in cell survival, proliferation, differentiation, migration, and metabolism. Research studies have examined the aberrant expression of signaling molecules that regulate PI3K/AKT pathway with the purpose of target discovery. The present review aims to recapitulate the relationship between the PI3K/AKT signaling pathway and factors contributing to initiation and development of various cancers. In addition, therapeutic interventions regulating this signaling pathway have been summarized.
(Copyright © 2022. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: